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607A Global Risk Approach to Identify Patients With Left Main or
3-Vessel Disease Who Could Safely and Efficaciously Be Treated
With Percutaneous Coronary Intervention
The SYNTAX Trial at 3 Years
Objectives The aim of this study was to assess the additional value of the Global Risk—a combina-
tion of the SYNTAX Score (SXscore) and additive EuroSCORE—in the identiﬁcation of a low-risk pop-
ulation, who could safely and efﬁcaciously be treated with coronary artery bypass graft surgery
(CABG) or percutaneous coronary intervention (PCI).
Background PCI is increasingly acceptable in appropriately selected patients with left main stem or
3-vessel coronary artery disease.
Methods Within the SYNTAX Trial (Synergy between PCI with TAXUS and Cardiac Surgery Trial), all-
cause death and major adverse cardiac and cerebrovascular events (MACCE) were analyzed at 36 months in
low (GRCLOW) to high Global Risk groups, with Kaplan-Meier, log-rank, and Cox regression analyses.
esults Within the randomized left main stem population (n  701), comparisons between GRCLOW
groups demonstrated a signiﬁcantly lower mortality with PCI compared with CABG (CABG: 7.5%, PCI:
1.2%, hazard ratio [HR]: 0.16, 95% conﬁdence interval [CI]: 0.03 to 0.70, p  0.0054) and a trend to-
ward reduced MACCE (CABG: 23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p  0.088). Similar
nalyses within the randomized 3-vessel disease population (n  1,088) demonstrated no statisti-
cally signiﬁcant differences in mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95% CI: 0.57 to 2.30, p  0.71)
r MACCE (CABG: 19.0%, PCI: 24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p  0.10). Risk-model performance
nd reclassiﬁcation analyses demonstrated that the EuroSCORE—with the added incremental beneﬁt of
he SXscore to form the Global Risk—enhanced the risk stratiﬁcation of all PCI patients.
onclusions In comparison with the SXscore, the Global Risk, with a simple treatment algorithm, substan-
ially enhances the identiﬁcation of low-risk patients who could safely and efﬁcaciously be treated with CABG
r PCI. (J Am Coll Cardiol Intv 2012;5:606–17) © 2012 by the American College of Cardiology Foundationa
r
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aThe SYNTAX score (SXscore) (1–4) has established itself
as an important tool in the SYNTAX trial (The Synergy
between PCI with TAXUS and Cardiac Surgery Trial)
pioneered Heart Team approach, in which the cardiac
surgeon and interventional cardiologist determined the
optimal revascularization modality for patients with un-
treated left main stem (LMS) or 3-vessel (3VD) coronary
artery disease (1,5–7). The SXscore has since been validated
in the LMS percutaneous coronary intervention (PCI)
From the *Department of Interventional Cardiology, Erasmus University, Medical
Centre, Thoraxcenter, Rotterdam, the Netherlands; †The Mayo Clinic, Rochester,
Minnesota; ‡Department of Cardiothoracic Surgery, Erasmus University, Medical
Centre, Thoraxcenter, Rotterdam, the Netherlands; §Medical City Dallas Hospital,
Dallas, Texas; Evanston Hospital, Evanston, Illinois; ¶Institut Jacques Cartier,
Massy, France; #University Hospital Uppsala, Uppsala, Sweden; **San Raffaele
Scientific Institute, Milan, Italy; ††Boston Scientific Corporation, Natick, Massa-
chusetts; ‡‡Cardialysis BV, Rotterdam, the Netherlands; §§Herzzentrum, Leipzig,
Germany; and the Department of Public Health, Erasmus University Medical
enter, Rotterdam, the Netherlands. The SYNTAX study was funded by Boston
cientific. Dr. Mack has served on the Speaker’s Bureau of Boston Scientific, Cordis,
M
apopulation at short- and long-term follow-up (8–11); the
3VD PCI population at short-term (1-year) follow-up
(12,13); and “All-Comers” patients undergoing PCI in
contemporary stent trials at 1-year follow-up (14,15). In
addition, both the current U.S. and European Guidelines on
myocardial revascularization (16–18) advocate the use of the
SXscore to determine the optimal revascularization modal-
ity in patients with unprotected left main or complex
coronary disease, without the explicit use of clinical vari-
nd Medtronic. Dr. Feldman serves on the Speaker’s Bureau of Boston Scientific;
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608ables. Furthermore, the U.S. guidelines now gives surgical
revascularization for unprotected left main coronary disease
a Class 1B recommendation (16,17), compared with a Class
1A recommendation in previous guidelines (19).
Because the SXscore relies on the scoring of the coronary
anatomy in isolation to objectively select the appropriate
revascularization strategy for the individual patient, criti-
cism has emerged, due to potentially important prognostic
information being missing secondary to the absence of
clinical factors (20,21). The EuroSCORE (22,23), a cardiac
surgery-based clinical risk score, has been shown to have a
reliable impact on prognosis and to be an independent predic-
tor of major adverse cardiac events and mortality in surgical and
percutaneously treated patients in the SYNTAX trial, thus
confirming findings from previous studies (24–28).
Attempts have previously been made to combine the SX-
score and additive EuroSCORE
to form the Global Risk classifi-
cation (29,30) and have been
shown to potentially improve the
risk stratification of patients un-
dergoing surgical or percutaneous
LMS intervention, compared
with the SXscore alone. The
Global Risk categorical approach
reported in the present study,
adapted from the previously re-
ported Global Risk classification
(29,30), uses the historically ac-
cepted cutoff levels for tertiles of the
additive EuroSCORE (22,23)—of
which a high EuroSCORE ter-
tile has previously been shown to
be an independent predictor of
adverse outcomes after PCI
(24,26 –28)—and the now
broadly accepted tertiles of the
SXscore (Fig. 1) (1–4). There-
fore the goal of the Global Risk is to improve in the
identification of low-risk groups with LMS or 3VD, com-
pared with the SXscore, who would achieve comparable
surgical and percutaneous outcomes in terms of efficacy and
safety at 3 years.
Methods
The SYNTAX trial is a randomized, prospective, multi-
center trial that incorporated an “All-Comers” design and
consisted of pre-specified LMS (isolated or associated with 1-,
2-, or 3-vessel disease) and 3VD cohorts (1,6,7). Patients were
randomized on a 1:1 basis to undergo either coronary artery
bypass graft surgery (CABG) or PCI or placed in nested
registries when considered unsuitable for randomization by
Abbreviations
and Acronyms
3VD  3-vessel disease
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
GRCLOW  Low Global Risk
GRCINT  Intermediate
Global Risk
GRCHIGH  High Global Risk
HR  hazard ratio
LMS  left main stem
MACCE  major adverse
cardiac and cerebrovascular
event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SXscore  SYNTAX Scorethe Heart Team (CABG nested registry for PCI-ineligiblepatients and PCI nested registry for CABG-ineligible
patients). Exclusions were only limited to patients with
prior coronary revascularization, the requirement of con-
comitant cardiac surgery, or ongoing acute myocardial
infarction (MI). Recent MI with resolution of cardiac
enzymes (2 upper limit of normal) and unstable angina
(no elevation in biomarkers) were not exclusion criteria.
The PCI techniques between the randomized and nested
registry populations were similar except that TAXUS Ex-
press (Boston Scientific Corporation, Natick, Massachu-
setts) paclitaxel-eluting stents were only permitted in the
randomized population. Within the PCI nested registry the
implantation of any type of drug-eluting stent or bare-metal
stent (BMS) was permitted, although the use of TAXUS
paclitaxel-eluting stents was encouraged. Of the 589 stents
implanted within the PCI nested registry, 57% were
TAXUS Express or Liberté (Boston Scientific Corpora-
tion), 19% were another drug-eluting stent, and 24% were
BMS; 4 PCI nested registry patients did not receive a stent.
Conversely CABG techniques between the randomized and
nested registry were broadly similar, except that double left and
right internal mammary artery grafts were more frequently
performed in the randomized (27.6%) CABG population, com-
pared with the CABG nested registry (16.1%).
The Global Risk was calculated by combining the SX-
score (2–4)—calculated by an independent core laboratory
(Cardialysis BV, Rotterdam, the Netherlands)—and the
additive EuroSCORE, as assessed by the Heart Team
before randomization (22,23). The additive EuroSCORE
Figure 1. The Proposed Global Risk
The Global Risk demonstrating recategorization of established tertiles of
risk for the SYNTAX Score and additive EuroSCORE to form low (GRCLOW),
intermediate (GRCINT), and high (GRCHIGH) Global Risk groups. Highlighted
(dashed) boxes indicate patients moved (reclassiﬁed) into or out of the
low SYNTAX Score group to form the low Global Risk group (GRCLOW).
Adapted from Capodanno et al. (29,30).was used to form the Global Risk, because this was shown
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609to be more predictive of clinical outcomes in the PCI
population compared with the logistic EuroSCORE, find-
ings consistent with a previous study (29). Patients were
subsequently categorized into 3 classes of Global Risk, on
the basis of predefined anatomical and clinical-risk catego-
ries (low, intermediate, and high) for the SXscore (2–4) and
additive EuroSCORE, respectively (22,23) (Fig. 1).
Statistical methods. Comparisons of all-cause death and major
dverse cardiac and cerebrovascular events (MACCE) (a compos-
te of all-cause death, MI, stroke, and all-cause revascular-
zation) (1,7) were performed (Kaplan-Meier curves) with
he log-rank test and Cox proportional hazard ratios be-
ween the low Global Risk (GRCLOW) groups for CABG
and PCI. This prognostic model-based approach to identify a
low subgroup of patients defined by prognostic factors is in
contrast to the traditional approach to subgroup analysis
(31–33). A logistic regression model that incorporated the
SXscore and EuroSCORE as covariates was used to give each
score proper relative weighting to each other within the Global
Risk. This analysis allowed for the assessment of the
predictive ability of the Global Risk: 1) the Hosmer–
Lemeshow test for calibration—the assessment of the cor-
rectness of the prediction by the risk model, with poor fit
indicated by a significant p value (0.05); 2) receiver
operator curves for discrimination (C-statistic)—the ability
of the risk model to appropriately assign the correct risk
prediction in patients who have the outcome, ranging from
0.50 (no discrimination) to 1.0 (perfect discrimination); 3) the
Brier score—an overall risk model performance measure cap-
turing both discrimination and calibration aspects of the risk
model, ranging from 0 to 1, with a lower value (closer to 0)
suggestive of a more predictive risk model (34–36). Compar-
isons were made with other risk models, namely, the SXscore
(2,4); age, creatinine, and ejection fraction/modified age, cre-
atinine, and ejection fraction scores (37,38); the Clinical
SXscore (39,40); and the additive/logistic EuroSCOREs
(22,23)—a brief description of which is enclosed in the Online
Appendix.
Analyses on those groups that were reclassified according
to the Global Risk compared with the SXscore alone were
Table 1. Comparison of Anatomical Factors (SXscore) and Clinical Risk Sc
Anatomical/Clinical
Risk Score
CABG
Randomized
(n  897)
Nested Registry
(n  644)
All-Comers
(n  1,541) p
SXscore 29.1 11.4 37.8 13.3 32.7 12.9 
Total Parsonnet score 8.4 6.8 9.0 7.1 8.7 6.9
Additive EuroSCORE 3.8 2.69 3.9 2.7 3.8 2.7
Logistic EuroSCORE, % 3.9 4.4 4.0 4.4 3.9 4.4
Mean score  1 SD. *p value represents comparisons between the All-Comers (randomized and
populations. †p value represents comparisons between the randomized and nested registry popu
SXscore SYNTAX Score.undertaken, following the principles of Net Reclassification sImprovement (38,41) (Fig. 1). These reclassification analy-
ses were to test whether the low Global Risk group
(GRCLOW) appropriately risk-stratified patients, compared
with a low SXscore. Higher anatomical risk patients (i.e.,
intermediate SXscores with low-intermediate Euro-
SCOREs) would be appropriately reclassified as lower-risk
(GRCLOW) if they had comparable (or more favorable) PCI
outcomes, compared with CABG. Conversely lower ana-
tomical risk patients with a high clinical comorbidity (i.e.,
low SXscore with a high EuroSCORE) would only be
appropriately reclassified to a higher risk group (GRCINT) if
they had more favorable surgical outcomes, compared with
PCI. Further detailed methodology, including illustrative
figures describing the reclassification concepts, is included
in the Online Appendix. A 2-sided p value 0.05 was
considered significant for all tests. All analyses were con-
ducted with SAS System Software (version 8.0 or higher,
SAS Institute, Cary, North Carolina) and SPSS (version
17.0, SPSS, Inc., Chicago, Illinois).
Results
All randomized patients underwent planned follow-up.
Within the nested registries, all PCI patients underwent
planned follow-up, and 649 of the 1,077 CABG patients
were randomly allocated for follow-up, on the basis of the
original study protocol (1,7). Complete data, including
clinical outcomes relating to the Global Risk, were
available in 1,789 of 1,800 randomized patients (PCI, n  899;
CABG, n  890), and 2,610 of 3,075 “All-Comers”
patients (PCI, n  1,088; CABG, n  1,522) at 3-year
ollow-up.
Within the randomized SYNTAX population baseline
emographic data and clinical characteristics for the treat-
ent arms have previously been described and were well-
alanced (1). Within the “All-Comers” population more
omplex coronary anatomy was present in the CABG
opulation (mean SXscore  1 SD: CABG: 32.7  12.9,
CI: 28.9  11.7, p  0.001) (Table 1). Conversely,
or the CABG and PCI Populations
PCI
p Value*
Randomized
(n  899)
Nested Registry
(n  195)
All-Comers
(n  1,094) p Value†
28.4 11.5 31.3 12.5 28.9 11.7 0.002 0.001
8.5 7.0 14.4 9.5 9.6 7.8 0.001 0.001
3.8 2.6 5.8 3.1 4.1 2.8 0.001 0.008
3.8 4.5 7.7 8.9 4.5 5.8 0.001 0.009
registry) coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI)
or the CABG and PCI populations.ores f
Value†
0.001
0.15
0.47
0.46
nested
lations fignificantly more comorbidity was present in the “All-
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610Comers” PCI population, as evidenced by significantly
greater Parsonnet (42) and EuroSCOREs (Table 1).
Clinical outcomes with PCI. Within the randomized and
“All-Comers” LMS (Fig. 2) and 3VD (Fig. 3) PCI popu-
lations, a low Global Risk group (GRCLOW) could be
differentiated from the higher risk groups (GRCINT-HIGH)
for All-Cause death and MACCE. Furthermore, within the
LMS PCI population, the Global Risk demonstrated a clear
incremental increase in predictive ability (C-statistics and
overall risk model performance measures), compared with
either the SXscore or the EuroSCORE in isolation (Fig. 4).
Within the randomized and “All-Comers” 3VD PCI pop-
ulation, the additive EuroSCORE had a superior predictive
ability for all-cause death and MACCE compared with the
SXscore alone, with little or no additional improvements in
the predictive ability of the Global Risk compared with the
additive EuroSCORE (Fig. 4).
Clinical outcomes with CABG. At 36 months the Global
Risk could differentiate between the GRCINT-HIGH groups
only for all-cause death and MACCE in the randomized
and “All-Comers” CABG populations (Figs. 2 and 3). The
Global Risk added little or no improvement to the predic-
tive ability, compared with the additive EuroSCORE used
in isolation (Fig. 4).
Comparison of CABG and PCI: low-risk LMS population.
Within the GRCLOW group of the randomized LMS
opulation (n  701), CABG resulted in significantly
higher 3-year mortality compared with PCI (CABG: 7.5%,
PCI: 1.2%, HR: 0.16, 95% CI: 0.03 to 0.70, p  0.0054),
with a trend toward a lower incidence of MACCE (CABG:
23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p 
0.088) and stroke (CABG: 3.5%, PCI: 0.6%, HR: 0.17,
95% CI: 0.02 to 1.46, p 0.067). No statistically significant
differences in MI or all-cause revascularization were found.
Within the GRCLOW group of the “All-Comers” LMS
opulation (n  1,079), no statistically significant differ-
nces in mortality (CABG: 5.3%, PCI: 2.7%, HR: 0.51,
5% CI: 0.18 to 1.44, p  0.19) or MACCE (CABG:
8.0%, PCI: 18.5%, HR: 1.02, 95% CI: 0.65 to 1.60, p 
.94) were observed. A significantly greater incidence of
troke was evident with CABG (CABG: 4.0%, PCI: 0.6%,
R: 0.13, 95% CI: 0.02 to 1.05, p  0.025), and a
ignificantly greater frequency of MI was evident with PCI
CABG: 0.9%, PCI: 3.9%, HR: 4.30, 95% CI: 0.89 to
0.70, p  0.047). No statistically significant differences in
ll-cause revascularization were seen (CABG: 10.7%, PCI:
4.8%, HR: 1.40, 95% CI: 0.81 to 2.42, p  0.23).
Comparison of CABG and PCI: low-risk 3VD population.
Within the GRCLOW group of the randomized 3VD popu-
lation (n  1,088), no statistically significant differences in
3-year mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95%
CI: 0.57 to 2.30, p 0.71) orMACCE (CABG: 19.0%, PCI:
24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p  0.10) were
observed. Percutaneous coronary intervention was associatedwith a significantly increased risk of all-cause revascularization
(CABG: 10.5%, PCI: 18.5%, HR: 1.88, 95% CI: 1.19 to 2.96,
p  0.0055). No statistically significant differences in the risk
of stroke were seen (CABG: 2.9%, PCI: 1.3%, HR: 0.45, 95%
CI: 0.13 to 1.49, p  0.18).
Within the “All-Comers” 3VD population (n  1,531)
no statistically significant differences in mortality were
observed (CABG: 5.1%, PCI: 5.9%, HR: 1.16, 95% CI:
0.62 to 2.17, p  0.65). A significantly higher incidence of
MACCE was evident with PCI (CABG: 17.9%, PCI:
24.4%, HR: 1.42, 95% CI: 1.03 to 1.96, p  0.031)
secondary to predominantly greater all-cause revasculariza-
tion (CABG: 9.1%, PCI: 18.5%, HR: 2.20, 95% CI: 1.44 to
3.35, p  0.0002). No statistically significant differences in
the incidences of stroke were seen (CABG: 3.2%, PCI:
1.5%, HR: 0.46, 95% CI: 0.16 to 1.30, p  0.13).
Analyses of reclassiﬁed patients. Within the LMS popula-
tion, patients (i.e., patients with an intermediate SXscore
and low-moderate EuroSCOREs) were appropriately re-
classified to the GRCLOW group (Fig. 1). More favorable
outcomes were seen with PCI, compared with CABG
(randomized population: 3-year all-cause death: CABG
10.8%, PCI 1.3%; 3-year MACCE: CABG 24.4%, PCI
15.6%). Conversely, patients reclassified to a higher-risk
(GRCINT) group (i.e., patients with a low SXscore and a
high EuroSCORE) had more favorable surgical outcomes
in the larger “All-Comers” population (Fig. 1), predomi-
nantly secondary to reduced MACCE with CABG (3-year
MACCE: CABG 20.4%, PCI 27.0%).
Within the 3VD population more favorable surgical outcomes
were evident in patients reclassified to the GRCLOW group.
urther analyses indicated that a GRCLOW with an intermediate
SXscore would remain better-managed by CABG, and a
GRCLOW with a low SXscore would have comparable surgical
nd PCI outcomes. More favorable surgical outcomes were
vident in patients (i.e., with a low SXscore and a high Euro-
CORE) reclassified to the higher-risk (GRCINT) group (ran-
domized population: 3-year death: CABG 9.6%, PCI 21.3%;
3-year MACCE: CABG 22.5%, PCI 39.1%). Further detailed
results of the reclassification analyses are included in the Online
Appendix.
Comparison of the Global Risk with other risk models. The
lobal Risk was superior in predictive performance com-
ared with other combined anatomical/clinical scores (de-
ived from the SXscore) and their components. This in-
luded the Clinical SXscore (39) (Fig. 4).
iscussion
The main findings of this study are: 1) clinical variables
(EuroSCORE) per se are more predictive of clinical outcomes
(all-cause death and MACCE), compared with anatomical
variables (SXscore) in the PCI population; 2) within the LMS
PCI population the Global Risk demonstrated a clear incre-
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611Figure 2. Comparisons of Clinical Outcomes by Categories of Global Risk in the SYNTAX LMS Population
Kaplan-Meier curves for cumulative rate of death (A) and MACCE (B) at 3-year follow-up stratiﬁed according to the Global Risk group; event rate  1.5 SE.
CABG  coronary arty bypass grafting; GRCLOW  Low Global Risk; GRCINT  Intermediate Global Risk; GRCHIGH  High Global Risk; LMS  left main stem;
MACCE  major adverse cardiac and cerebrovascular event(s); PCI  percutaneous coronary intervention.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 6 , 2 0 1 2
J U N E 2 0 1 2 : 6 0 6 – 1 7
Serruys et al.
SYNTAX at 3 Years: LM or 3VD Treated With PCI
612Figure 3. Comparisons of Clinical Outcomes by Categories of Global Risk in the SYNTAX 3VD Population
Kaplan-Meier curves for cumulative rate of death (A) and MACCE (B), at 3-year follow-up stratiﬁed according to the Global Risk group; event rate  1.5 SE.
3VD  3-vessel disease; other abbreviations as in Figure 2.
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613mental benefit in its predictive ability, compared with the
Xscore or EuroSCORE used in isolation; 3) within the
VD PCI population, the Global Risk improved the risk
tratification of patients, compared with the SXscore alone,
y demonstrating that low SXscore patients with a high
uroSCORE to attain a mortality benefit in undergoing
ABG compared to PCI; and 4) that the Global Risk
ubstantially enhanced the identification of a low-risk pop-
lation who could safely and efficaciously be treated with
Figure 4. Comparison of Different Risk Models for the Randomized LMS an
Comparison of different risk models for the randomized LMS and 3VD populat
test), discrimination (C-statistic, y axes), and overall model performance measu
incremental beneﬁt, in terms of predictive ability, of the Global Risk compared
tistic and lower Brier score. Yellow arrows in the 3VD cohort demonstrate the
with little/no improvement of the predictive ability of the Global Risk compare
scores. Note how even minor differences in the Brier score reﬂect overall impr
for death and MACCE reﬂecting the ﬁndings that the risk models are superior
clinical SYNTAX score; other abbreviations as in Figures 2 and 3.ABG or PCI at 3 years.The application of the Global Risk to the SYNTAX
population was complicated by the differing prognostic and
morbidity outcomes between the LMS and 3VD popula-
tions. However, a low-risk population was identified with
outcomes comparable to CABG and PCI at 3 years in terms
of efficacy and safety, namely a GRCLOW group in the LMS
opulation and a GRCLOW group with a low SXscore in the
3VD population. Ultimately reclassification analyses proved
vital in ensuring the optimal revascularization modality in
Populations for Death and MACCE at 3 Years
or death (A) and MACCE (B) at 3 years, with calibration (Hosmer–Lemeshow
rier score, x axes) (36). Yellow arrows in the LMS cohort demonstrate the
the additive EuroSCORE and SYNTAX Score as evidenced by a greater C-sta-
mental beneﬁt of the additive EuroSCORE compared with the SYNTAX Score
h the additive EuroSCORE, as evidenced by comparable C-statistics and Brier
nts in the model performance and the different scales for the Brier scores
dicting death. ACEF  age, creatinine, and ejection fraction (score); CSS d 3VD
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614patients with a low SXscore were shown to confer a clear
mortality benefit from undergoing CABG in the 3VD
population, and intermediate-SXscore patients with low-
moderate EuroSCOREs were shown to confer a potential
survival advantage in undergoing PCI in the LMS population.
On the basis of these findings a treatment algorithm is
proposed to simplify these concepts, which admittedly will
require further validation in other unselected registries (Fig. 5).
The main strengths of the Global Risk are that the
additive EuroSCORE is a simple bedside calculation and
that the Global Risk can be applied across the entire
spectrum of surgical and percutaneously treated patients.
Within the “All-Comers” SYNTAX population the adop-
tion of this treatment algorithm (Fig. 5) would potentially
identify a smaller population of patients, compared with
using the SXscore alone, who would have similar outcomes
to CABG and PCI at 3 years in terms of efficacy and
safety—namely, 39% of the LMS population (compared
with 51% with low-moderate SXscores) and 21% of the
3VD population (compared with 26% with a low SXscore).
By identifying a low Global Risk (GRCLOW) group
ithin the randomized LMS population, a significant mor-
ality benefit and trend toward a reduction in MACCE was
vident for PCI at 3 years. This was not apparent in the
All-Comers” population. Several factors might explain this
isparity in results. First, the “All-Comers” PCI population
ad significantly greater comorbidity (Table 1)—factors
ell known to be associated with in-hospital and long-term
dverse outcomes after PCI (24,26–28). Second, a low
uroSCORE could not exclude nonadjustable characteris-
ics, such as the judgment of the treating clinician in
eclining a patient for CABG and thus undergoing PCI
nstead, such as patients with a short-term survival—as were
ecruited within the “All-Comers” SYNTAX trial. Third,
he CABG nested registry might potentially have been
Figure 5. Proposed Treatment Algorithm for the Management of LMS and 3
Proposed treatment algorithm for the management of LMS and 3VD incorpora
Although not explicitly stated PCI might be the preferred revascularization mo
threshold of operative risk is exceeded for the patient and cardiac surgeon, co
stratiﬁcation should be undertaken. Abbreviations as in Figures 2 and 3.iluted with a proportion of lower-anatomical-risk patients
ho might have been suitable for PCI, because the concept
f the clinical outcomes on the basis of tertiles of the
Xscore were unknown at the time of the SYNTAX trial.
ourth, is the use of BMS in the nested PCI registries:
lthough specific data pertaining to the indications for use of
MS were not collected, it is probable that a sizeable propor-
ion of these patients might have had comorbidities that
recluded the use of prolonged dual antiplatelet therapy. The
doption of the “All-Comers” approach is nonetheless more
ikely to mirror contemporary clinical practice and is perceived
y many as the recommended approach (18,43).
Adverse clinical comorbidity: CABG or PCI? In both the LMS
nd 3VD populations the surgical benefit in the higher
omorbidity patients (i.e., with a low SXscore and high
uroSCORE) was more pronounced, compared with PCI.
n particular a substantial mortality benefit favoring CABG
as evident in low-SXscore patients with a high Euro-
CORE in the 3VD population. Although it has been
reviously demonstrated that a high EuroSCORE is a
otential predictor of adverse outcomes after PCI (24,26–
8), conventional clinical practice has suggested that high-
omorbidity patients might be more suitable for PCI com-
ared with CABG. In contrast to this accepted clinical
ractice, it seems that it is precisely these types of patients
ho would potentially stand to gain more from CABG on
rognostic and morbidity grounds. These findings are prob-
bly related to PCI treating the individual lesion, whereas
ABG would potentially protect the entire treated vessel
rom future cardiac events for the lifespan of the graft.
There is nevertheless a recognition that a certain threshold
f operative risk would have to be acceptable for the cardiac
urgeon and patient, and the latter of who may adamantly
efuse a surgical approach due to the anticipated prohibitive
isk of the proposed surgical intervention. It should, however,
corporating Clinical and Anatomical Variables
linical (additive EuroSCORE) and anatomical (SYNTAX Score) variables.
in low-risk patients subject to the Heart Team discussion. *If an acceptable
ation of PCI should be considered—appropriate discussion concerning riskVD In
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615be recognized that PCI may potentially be more hazardous for
the patient with regard to long-term outcomes, compared with
CABG. A greater understanding of this phenomenon may
potentially reduce the threshold value for which surgical
revascularization is declined during theHeart Team discussion.
Anatomical and clinical variables in the LMS PCI population.
Before the introduction of the SXscore, heterogeneity of the
LMS anatomical description and its impact on clinical
outcomes were previously recognized by the use of classical
terminology describing isolated LMS or LMS  1-, 2-, or
3-vessel disease. The SXscore was an attempt to eliminate the
historical and arbitrarily defined subdivisions of the coronary
tree into LMS and 3VD and to create a common anatomical
denominator (2,3). It now seems that the LMS outcomes are
largely a reflection of the presence of distal LMS bifurcation
disease, clinical comorbidity, and importantly, the increasing
prevalence of 3VD and its association with clinical comorbidi-
ties (as discussed in the following) and anatomical complexi-
ties, such as multiple bifurcations and the presence of total
occlusions leading to higher SXscores.
Anatomical and clinical variables in the 3VD PCI population.
Within the 3VD PCI population the SXscore added very little
incremental benefit to the additive EuroSCORE in predicting
death andMACCE (Fig. 4). It might be hypothesized that the
severity of 3VD (as evidenced by a higher SXscore) might be
representative of patients with a more adverse risk profile who
have evidence of systemic atherosclerosis and therefore are at
greater longer-term cardiovascular and cerebrovascular risk. Con-
sequently these patients might potentially benefit fromCABGon
prognostic and morbidity grounds due to the bypass grafts
protecting the coronary vessel as discussed. This might also be an
explanation for the comparability in long-term stroke outcomes
betweenCABG and PCI for the 3VDSYNTAXpopulation (6).
This hypothesis is supported by the significant and direct
elationship of the 10-year predicted Framingham risk
cores with the prevalence and magnitude of coronary artery
alcium scores (44). Furthermore, the ankle-brachial pres-
ure index (45–49) and common carotid intima-media
hickness (50–53), both markers of peripheral vascular
isease, have been correlated with the severity of coronary
rtery disease and clinical events.
Implications of the Global Risk for future trials. Given the
heterogeneity of the outcomes between LMS and 3VD,
the strategy for the future is to construct separate trials for
the LMS and 3VD populations that should incorporate
anatomical and clinical variables. Left main stem disease is
currently subject to the ongoing EXCEL (Evaluation of
Xience Prime or Xience V versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization) trial,
recruiting patients on anatomical entry criteria only—namely
low-moderate SXscores—and does not directly take into account
clinical variables except within the Heart Team discussion.
Within the 3VD population perhaps a more targeted
identification of patients by other markers of atheroscleroticburden, such as ankle-brachial pressure index and common
carotid intima-media thickness as discussed, in conjunction
with the SXscore or Global Risk might prove beneficial.
Another recently described approach is the “Functional
SYNTAX Score”—utilizing the functional assessment of
coronary lesions—and has potentially been shown to im-
prove the identification of low and higher risk patients (54).
In addition, the potential noninvasive calculation of the Func-
tional SYNTAX Score, with computational fluid dynamics
applied to coronary computed tomography angiography, has
shown significant promise (55,56).
Summary of the potential clinical implications of the Global Risk.
The practical clinical application of the Global Risk is
summarized in a treatment algorithm in Figure 5. Although
validation of the Global Risk concept is required, the practi-
calities are that not only high-anatomical-risk patients but also
patients with significant comorbidity are best served by under-
going surgical revascularization, because they seem to be one of
the patient groups that stand to potentially gain more from
surgical revascularization on prognostic and morbidity grounds,
particularly if they have 3VD. Clearly a threshold of operative risk
for surgical revascularization should not be exceeded; therefore
these issues are vital in theHeart Team discussion in selecting the
most appropriate revascularization modality.
Study limitations. This study represents a post hoc analysis
of the original SYNTAX Trial, and the predictive models
were developed retrospectively at 3-year follow-up. The
further analyses undertaken in the LMS and 3VD cohorts
(1,7) should be considered as hypothesis-generating. Fur-
thermore, the focus of this study was on low Global risk
(GRCLOW) groups, because CABG is the standard of care
in the management of patients in the higher-Global Risk
groups (1,5,6). Comparisons between the higher-Global
Risk groups are nevertheless provided in the Online Ap-
pendix. In addition there was limited statistical power for
the comparison between CABG and PCI for events such as
stroke and MI and analyses of reclassified patients. Conse-
quently external validation of the proposed Global Risk is
required in unselected registries, with numbers greater than
the SYNTAX “All-Comers” population. The “All-Comers”
concept of the SYNTAX trial, although more representative
of contemporary clinical practice compared with the ran-
domized approach (18,43), has been reported to potentially
not result in the inclusion of consecutive patients, predom-
inantly due to the inability to gain appropriate informed
consent and refusal to participate (57).
It is not possible to judge and account for the decisions
made by the Heart Team in selecting a patient for random-
ization. However, this approach is representative of contem-
porary practice. It should also be acknowledged that, although
the SYNTAX Trial was based on contemporary revasculariza-
tion practice at the time, improvements in technology in both
CABG and PCI might yield differences in clinical outcomes in
future trials. Noninvasive or invasive carotid imaging to screen
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616for the presence of significant carotid disease was undertaken
by the clinical consensus of the Heart Team to calculate the
EuroSCORE. The possibility of a small minority of patients
with clinically silent carotid disease cannot be excluded. The
cardiac-related comorbidities within the EuroSCORE are
more likely to reflect outcomes after PCI, whereas extracardiac
factors (e.g., the presence of chronic obstructive pulmonary
disease and poor neurological status) are unlikely to reflect
outcomes (24–28)—this point should be borne in mind when
interpreting the Global Risk. Furthermore, the use of the
EuroSCORE with a continuous approach might have affected
the results of the analysis. However, the categorical approach
was adopted from the outset to allow application of the same
risk model in CABG and PCI patients, given that a high
SXscore tertile has consistently been shown to be an indepen-
dent predictor of adverse outcomes after PCI (24,26–28). The
newly developed EuroSCORE II (58) cannot be applied to the
concept of the Global Risk, because this information was not
collected during the original SYNTAX trial.
Conclusions
In comparison with the SXscore, the Global Risk—with a
simplified treatment algorithm—substantially enhances the
identification of low-risk patients who could safely and
efficaciously be treated with CABG or PCI.
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